Drug intelligence / Profile preview

aderbasib + docetaxel

Development stage: Discontinued
Lead developer: Incyte
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination of aderbasib (INCB007839), an ADAM10 and ADAM17 protease inhibitor, with docetaxel, a taxane chemotherapy agent. Aderbasib inhibits the metalloproteinase 'sheddase' activities of ADAM10 and ADAM17, which may result in inhibition of tumor cell proliferation. INCB007839 has been investigated in clinical trials for solid tumors including breast cancer and high-grade gliomas.

Targets

ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10)ADAM17 (A disintegrin and metalloprotease 17)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on aderbasib + docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aderbasib + docetaxel.